share_log

Eli Lilly and Co | SC TO-T/A: Third party tender offer statement (Amendment)

Eli Lilly and Co | SC TO-T/A: Third party tender offer statement (Amendment)

禮來 | SC TO-T/A：發行招標公告
美股SEC公告 ·  08/01 06:12

Moomoo AI 已提取核心訊息

Eli Lilly and Company, through its wholly-owned subsidiary Rainier Acquisition Corporation, has launched a tender offer to acquire all outstanding shares of Morphic Holding, Inc. at a price of $57.00 per share in cash. The offer, which commenced on July 19, 2024, is set to expire at 11:59 P.M., Eastern Time, on August 15, 2024, unless extended or terminated earlier. A key condition for the offer, the Regulatory Condition, was met with the expiration of the HSR Act waiting period on July 31, 2024. The completion of the tender offer is subject to other conditions detailed in the Offer to Purchase. The offer represents a strategic move by Eli Lilly to expand its holdings, and the acquisition process is being overseen by executives Anat Hakim and Michael C. Thompson, with legal counsel provided by Kirkland & Ellis LLP.
Eli Lilly and Company, through its wholly-owned subsidiary Rainier Acquisition Corporation, has launched a tender offer to acquire all outstanding shares of Morphic Holding, Inc. at a price of $57.00 per share in cash. The offer, which commenced on July 19, 2024, is set to expire at 11:59 P.M., Eastern Time, on August 15, 2024, unless extended or terminated earlier. A key condition for the offer, the Regulatory Condition, was met with the expiration of the HSR Act waiting period on July 31, 2024. The completion of the tender offer is subject to other conditions detailed in the Offer to Purchase. The offer represents a strategic move by Eli Lilly to expand its holdings, and the acquisition process is being overseen by executives Anat Hakim and Michael C. Thompson, with legal counsel provided by Kirkland & Ellis LLP.
依利愛與公司通過其全資子公司Rainier Acquisition Corporation，以每股57.00美元的現金價格發起要約收購Morphic Holding，Inc.的所有未流通股份。該要約於2024年7月19日啓動，將於2024年8月15日11:59 P.m.東部時間到期，除非提前延長或終止。要約的關鍵條件控件已經隨着2024年7月31日HSR Act等待期的到期而實現。要約的完成還受其他條件的限制，詳見要約書。對於Eli Lilly來說，這是一次擴大控制權的戰略舉措，收購過程由Anat Hakim和Michael C. Thompson執行，並由Kirkland & Ellis LLP提供法律諮詢。
依利愛與公司通過其全資子公司Rainier Acquisition Corporation，以每股57.00美元的現金價格發起要約收購Morphic Holding，Inc.的所有未流通股份。該要約於2024年7月19日啓動，將於2024年8月15日11:59 P.m.東部時間到期，除非提前延長或終止。要約的關鍵條件控件已經隨着2024年7月31日HSR Act等待期的到期而實現。要約的完成還受其他條件的限制，詳見要約書。對於Eli Lilly來說，這是一次擴大控制權的戰略舉措，收購過程由Anat Hakim和Michael C. Thompson執行，並由Kirkland & Ellis LLP提供法律諮詢。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間